Funding Roundup: IRX, Genesis, Inimex, VeraLight and ONCODESIGN

This post was commissioned on June 3, 2008, and it was categorized as Venture Capital.

Feel free to leave a comment below. Eben loves comments. You may also subscribe to comments through this RSS Comments feed or trackback here.

Busy day on the funding side today. Too many to keep up with and I’m pretty sure I missed a couple but, no time for whining:

ONCODESIGN Secures 4.7M in Financing
VeraLight secures $20 million series C financing for a non-invasive diabetes screening system
IRX therapeutics completes $25 million series A preferred stock offering to continue clinical development of the phase II cancer drug, IRX-2 (citoplurikin), for head and neck cancers.
Inimex raises $22 million to fund and IND and clinical trials for its antibiotic resistance drug.
Genesis pharmaceuticals enterprises (China) closes $30 million private note placement to pay for the rights to manufacture a new Chinese drug for the heart called Ligustrazine Ferulic Acid Acetate, or LFAA for short.
AxoGen is provided with $7.5 million venture loan to advance their peripheral nerve repair system, AVANCE.

Theoretically Related Posts

July 7, 2008 -- Secretive Agios Makes Splash with $33M Series A (0)
June 9, 2008 -- Drug Development: From Discovery to NDA (2)
April 16, 2009 -- Lycera Closes $36 Million Series A (0)
April 15, 2009 -- Synageva Nets $30M (0)
December 4, 2008 -- Catalyst Biosciences Raises $40 Million in Series C Financing (1)
November 17, 2008 -- Zafgen Raises $14 Million in Series B (0)
November 17, 2008 -- Pacira Pharmaceuticals Raises $85 Million in Series A (2)
November 11, 2008 -- Accera Completes $35 Million Series C Financing (1)
October 22, 2008 -- Neuroptix Raises $18.5 Million in Successful B Round (0)
October 22, 2008 -- Apitope Raises EUR 10 Million in Series A Financing (0)

This post was constructed by

Eben Tessari

.

Eben is a highly caffeinated business development associate at a small, cash sensitive pharmaceutical company somewhere in Massachusetts. He enjoys cliche-less banter, compartmentalization, non-equilibrium thermodynamics and NPV analysis. Agree or disagree with what he's posted? He encourages comments.

If one were so inclined, one could follow him at any of these fine web 2.0 establishments: